natgillin/translations-raw huggingface dataset:
The safety profile of sildenafil is based on 9,570 patients in 74 double-blind placebo-controlled clinical studies. 
Profil sigurnosti sildenafila temelji se na podacima dobivenim od 9570 bolesnika koji su sudjelovali u 74 dvostruko slijepa, placebom kontrolirana klinička ispitivanja.
You should NOT take this medicine - if you are already undergoing other treatments for erectile dysfunction. 
NE smijete uzimati ovaj lijek - ako već uzimate druge terapije za erektilnu disfunkciju.
Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and not eliminated in the urine. 
Ne očekuje se da renalna dijaliza ubrza klirens jer je sildenafil u velikoj mjeri vezan na proteine plazme i ne eliminira se urinom.
- if you have recently had a stroke or a heart attack. 
4. ako ste nedavno imali moždani ili srčani udar.
If you are taking ritonavir, you may not exceed a maximum dose of 25 mg sildenafil within a period of 48 hours. 
Ako uzimate ritonavir, ne smijete uzeti dozu veću od 25 mg sildenafila u razdoblju od 48 sati.
Paediatric population Sildenafil ratiopharm is not indicated for individuals below 18 years of age. 
Pedijatrijska populacija Sildenafil ratiopharm nije indiciran za primjenu u osoba mlađih od 18 godina.
Sildenafil had no effect on ritonavir pharmacokinetics. 
Sildenafil nije imao učinak na farmakokinetiku ritonavira.
In a separate RigiScan study, sildenafil was still able to produce an erection in response to sexual stimulation 4-5 hours post-dose. 
U zasebnom RigiScan ispitivanju, sildenafil je još uvijek bio u mogućnosti dovesti do erekcije u odgovoru na seksualnu stimulaciju 4-5 sati nakon doziranja.
This is when a man cannot get or keep a hard, erect penis suitable for sexual activity. 
Do toga dolazi kada muškarac nije u mogućnosti postići ili održati ukrućenost penisa u mjeri dovoljnoj za primjerenu spolnu aktivnost.
If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. 
Ako se prijapizam odmah ne liječi, moguće je oštećenje tkiva penisa i trajan gubitak potencije.
If you take more Sildenafil ratiopharm than you should, tell your doctor. 
Ako ste uzeli više tableta Sildenafil ratiopharm nego što trebate, javite se svom liječniku.
Two clinical studies were specifically designed to assess the time window after dosing during which sildenafil could produce an erection in response to sexual stimulation. 
Dva klinička ispitivanja posebno su dizajnirana kako bi se procijenio vremenski okvir nakon doziranja tijekom kojeg bi sildenafil mogao dovesti do erekcije u odgovoru na seksualnu stimulaciju.
Sildenafil is an oral therapy for erectile dysfunction. 
Sildenafil je oralna terapija za erektilnu disfunkciju.
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing sildenafil in all subsets of the paediatric population for the treatment of erectile dysfunction (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove je izuzela obvezu podnošenja rezultata ispitivanja ovog lijeka koji sadrži sildenafil u svim podskupinama pedijatrijske populacije za liječenje erektilne disfunkcije (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
These symptoms usually occur within 4 hours of taking Sildenafil ratiopharm. 
Ti se simptomi obično javljaju unutar 4 sata od primjene lijeka Sildenafil ratiopharm.
In single dose volunteer studies of doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased. 
U ispitivanjima s jednokratnim dozama do 800 mg primijenjenim na dobrovoljcima, nuspojave su bile slične onima uočenim pri nižim dozama, međutim stope incidencije i težina bile su povećane.
Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue. 
Sildenafil nema izravni relaksirajući učinak na izolirani ljudski korpus kavernozum, ali izrazito pojačava relaksirajući učinak NO na to tkivo.
Talk to your doctor or pharmacist before taking Sildenafil ratiopharm - if you have problems with your heart. 
Obratite se svom liječniku ili ljekarniku prije nego uzmete Sildenafil ratiopharm. - ako imate problema sa srcem.
After a single oral dose of 100 mg, the mean maximum total plasma concentration of sildenafil is approximately 440 ng/mL (CV 40%). 
Nakon jednokratne oralne doze od 100 mg, srednja maksimalna ukupna koncentracija sildenafila u plazmi iznosi približno 440 ng/ml (CV 40%).
Mild and transient differences in colour discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose. 
Blage i prolazne razlike u raspoznavanju boja (plava/zelena) opažene su u nekih ispitanika uz primjenu Farnsworth-Munsell 100 hue testa kod 1 sata nakon doze od 100 mg, bez učinaka vidljivih nakon 2 sata poslije primjene doze.
Sildenafil has no effect on visual acuity or contrast sensitivity. 
Sildenafil nema učinak na oštrinu vida ili osjetljivost na kontrast.
Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 > 150 µM). 
Sildenafil je slabi inhibitor citokroma P450 izoformi 1A2, 2C9, 2C19, 2D6, 2E1 i 3A4 (IC50 >150 µM).
Posology Use in adults 
Primjena u odraslih osoba
The mean steady state volume of distribution (Vd) for sildenafil is 105 l, indicating distribution into the tissues. 
Srednji volumen distribucije u stanju dinamičke ravnoteže (Vd) za sildenafil iznosi 105 l, što ukazuje na distribuciju u tkiva.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu. 
Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove http://www.ema.europa.eu/.
A double-blind, placebo-controlled exercise stress trial evaluated 144 patients with erectile dysfunction and chronic stable angina who regularly received anti-anginal medicinal products (except nitrates). 
U dvostruko slijepom, placebom kontroliranom ispitivanju stresa izazvanog vježbanjem procijenjeno je 144 bolesnika s erektilnom disfunkcijom i kroničnom stabilnom anginom koji su redovito uzimali lijekove protiv angine (osim nitrata).
Table 1: Medically important adverse reactions reported at an incidence greater than placebo in controlled clinical studies and medically important adverse reactions reported through postmarketing surveillance 
Tablica 1: Medicinski značajne nuspojave zabilježene s incidencijom većom od placeba u kontroliranim kliničkim ispitivanjima i medicinski značajne nuspojave zabilježene u razdoblju nakon stavljanja lijeka u promet
Use in patients taking other medicinal products 
Primjena u bolesnika koji uzimaju druge lijekove
Single doses of antacid (magnesium hydroxide/aluminium hydroxide) did not affect the bioavailability of sildenafil. 
Jednokratne doze antacida (magnezijev hidroksid/aluminijev hidroksid) nisu utjecale na bioraspoloživost sildenafila.
Sildenafil potentiates the hypotensive effect of nitrates (see section 4.3). 
Sildenafil pojačava hipotenzivne učinke nitrata (vidjeti dio 4.3).
After oral dosing of sildenafil AUC and Cmax increase in proportion with dose over the recommended dose range (25-100 mg). 
Nakon oralnog doziranja sildenafila AUC i Cmax rastu proporcionalno s dozom u preporučenom rasponu doze (25-100 mg).
Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG. 
Jednokratne oralne doze sildenafila do 100 mg u zdravih dobrovoljaca nisu dovela do klinički značajnih učinaka na EKG.
These are symptoms of a fall in blood pressure upon rising quickly from sitting or lying (postural hypotension). 
To su simptomi pada krvnog tlaka nakon naglog ustajanja iz sjedećeg ili ležećeg položaja (posturalna hipotenzija).
As dizziness and altered vision were reported in clinical trials with sildenafil, patients should be aware of how they react to sildenafil, before driving or operating machinery. 
Budući da su omaglica i poremećaj vida zabilježeni u kliničkim ispitivanjima sa sildenafilom, bolesnici moraju uzeti u obzir način na koji oni reagiraju na sildenafil, prije upravljanja vozilima ili rada sa strojevima.
Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. 
Dušikov oksid zatim aktivira enzim gvanilat ciklazu, što rezultira porastom razina cikličnog gvanozin monofosfata (cGMP), što dovodi do relaksacije glatkih mišića u korpus kavernozumu omogućavajući dotok krvi.
Some patients taking alpha blockers may experience dizziness or light-headedness when getting up. 
Neki bolesnici koji uzimaju alfa-blokatore mogu osjetiti omaglicu ili ošamućenost pri ustajanju.
Epistaxis, Sinus congestion 
Epistaksa, sinusna kongestija
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency [very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000)]. 
U donjoj tablici navedene su sve medicinski značajne nuspojave, koje su se javile u kliničkim ispitivanjima s učestalošću većom nego kod placeba, razvrstane prema organskim sustavima i učestalosti (vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000).
In vivo studies 
In vivo ispitivanja:
Sildenafil causes mild and transient decreases in blood pressure which, in the majority of cases, do not translate into clinical effects. 
Sildenafil uzrokuje blago i prolazno sniženje krvnog tlaka koje u većini slučajeva ne dovodi do kliničkih učinaka.
Sildenafil ratiopharm is indicated in adult men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. 
Sildenafil ratiopharm je indiciran je u odraslih muškaraca s erektilnom disfunkcijom, odnosno nemogućnošću postizanja ili održavanja penilne erekcije dostatne za zadovoljavajuću seksualnu aktivnost.
In healthy volunteers receiving sildenafil (100 mg single dose), less than 0.0002% (average 188 ng) of the administered dose was present in ejaculate 90 minutes after dosing. 
U zdravih dobrovoljaca koji su primali sildenafil (100 mg u jednokratnoj dozi), manje od 0,0002% (prosječno 188 ng) primijenjene doze prisutno je u ejakulatu 90 minuta nakon doziranja.
The postulated mechanism for this change in colour discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina. 
Pretpostavljeni mehanizam za ovu promjenu u raspoznavanju boje povezan je s inhibicijom PDE6, koja je uključena u fototransdukcijsku kaskadu mrežnice.
From post-marketing experience cases of unstable angina (a heart condition) and sudden death have been reported rarely. 
Nakon stavljanja lijeka u promet prijavljeni su rijetki slučajevi nestabilne angine (srčani poremećaj) i iznenadne smrti.
When sildenafil and doxazosin were administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports of patients who experienced symptomatic postural hypotension. 
Kada su sildenafil i doksazosin istodobno primjenjivani bolesnicima stabiliziranima na terapiji doksazosinom, bilo je povremenih izvještaja o bolesnicima koji su imali simptomatsku posturalnu hipotenziju.
Sildenafil has a peripheral site of action on erections. 
Sildenafil ima periferno mjesto djelovanja na erekcije.
- An allergic reaction - this occurs uncommonly (may affect up to 1 in 100 people). 
Alergijska reakcija - javlja se manje često (može se javiti u najviše 1 na 100 osoba).
Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 80 mg/dl. 
Sildenafil (50 mg) nije potencirao hipotenzivne učinke alkohola u zdravih dobrovoljaca sa srednjim maksimalnim razinama alkohola u krvi od 80 mg/dl.
If sildenafil is taken with food, the onset of activity may be delayed compared to the fasted state (see section 5.2). 
Ako se sildenafil uzima s hranom, nastup djelovanja može biti odgođen u usporedbi s uzimanjem natašte (vidjeti dio 5.2).
If you experience any of the following serious side effects stop taking Sildenafil ratiopharm and seek medical help immediately: 
Ako primijetite bilo koju od sljedećih ozbiljnih nuspojava, prestanite uzimati Sildenafil ratiopharm i odmah zatražite medicinsku pomoć:
When sildenafil is taken with food, the rate of absorption is reduced with a mean delay in tmax of 60 minutes and a mean reduction in Cmax of 29%. 
Prilikom uzimanja sildenafila s hranom, brzina apsorpcije je smanjena sa srednjom odgodom tmax od 60 minuta i srednjim smanjenjem Cmax od 29%.
What you need to know before you take Sildenafil ratiopharm 
Što morate znati prije nego počnete uzimati Sildenafil ratiopharm
Given sildenafil peak plasma concentrations of approximately 1 µM after recommended doses, it is unlikely that sildenafil will alter the clearance of substrates of these isoenzymes. 
S obzirom da su nakon preporučenih doza vršne koncentracije sildenafila u plazmi približno 1 µM, nije vjerojatno da će sildenafil promijeniti klirens supstrata tih izoenzima.
The following groups were not well represented or excluded from clinical trials: patients with pelvic surgery, patients post-radiotherapy, patients with severe renal or hepatic impairment and patients with certain cardiovascular conditions (see section 4.3). 
Sljedeće skupine nisu dobro zastupljene ili su isključene iz kliničkih ispitivanja: bolesnici s operacijom u području zdjelice, bolesnici nakon radioterapije, bolesnici s teškim poremećajem funkcije bubrega ili jetre i bolesnici s određenim kardiovaskularnim stanjima (vidjeti dio 4.3).
In a penile plethysmography (RigiScan) study of fasted patients, the median time to onset for those who obtained erections of 60% rigidity (sufficient for sexual intercourse) was 25 minutes (range 12-37 minutes) on sildenafil. 
Ispitivanjem pomoću penilne pletizmografije (RigiScan) u bolesnika natašte, medijan vremena do pojave za one koji su postigli erekcije od 60% rigiditeta (dovoljno za spolni odnos) iznosila je 25 minuta (raspon 12-37 minuta) za sildenafil.
Since sildenafil (and its major circulating N-desmethyl metabolite) is 96% bound to plasma proteins, this results in the mean maximum free plasma concentration for sildenafil of 18 ng/mL (38 nM). 
Budući da je sildenafil (i njegov glavni cirkulirajući N-dezmetil metabolit) 96% vezan na proteine u plazmi, to rezultira srednjom maksimalnom koncentracijom slobodnog sildenafila u plazmi od 18 ng/ml (38 nM).
The major circulating metabolite results from N-demethylation of sildenafil. 
Glavni cirkulirajući metabolit nastaje N-demetilacijom sildenafila.
Sildenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1). 
Sildenafil ima vazodilatatorna svojstva, što rezultira blagim i prolaznim sniženjem krvnog tlaka (vidjeti dio 5.1).
There was no evidence of favourable clinical effect of the combination in the population studied. 
U ispitivanoj populaciji nije dokazan povoljan klinički učinak kombinirane terapije.
This is most likely to occur within 4 hours post sildenafil dosing (see sections 4.2 and 4.4). 
Do toga će najvjerojatnije doći unutar 4 sata nakon primjene doze sildenafila (vidjeti dijelove 4.2 i 4.4).
Sildenafil had no effect on saquinavir pharmacokinetics (see section 4.2). 
Sildenafil nije imao učinka na farmakokinetiku sakvinavira (vidjeti dio 4.2).
In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite. 
U normalnih, zdravih muških dobrovoljaca, nije bilo dokaza o utjecaju azitromicina (500 mg dnevno tijekom 3 dana) na AUC, Cmax, tmax, konstantu brzine eliminacije ili poluvrijeme sildenafila ili njegovog glavnog cirkulirajućeg metabolita.
There is no safety information on the administration of sildenafil to patients with bleeding disorders or active peptic ulceration. 
Nema informacija o sigurnosti primjene sildenafila u bolesnika s poremećajima krvarenja ili aktivnim peptičnim ulkusom.
Studies in vitro have shown that sildenafil is selective for PDE5, which is involved in the erection process. 
In vitro ispitivanja pokazala su da je sildenafil selektivan za PDE5, koja je uključena u proces erekcije.
At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was administered alone. 
U 24 sata, razine sildenafila u plazmi bile su još uvijek približno 200 ng/ml, u usporedbi s približno 5 ng/ml kada se sildenafil davao zasebno.
Therefore, concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma concentrations of sildenafil. 
Zbog toga se kod istodobne primjene jakih CYP3A4 induktora, kao što je rifampin, očekuju veća smanjenja koncentracije sildenafila u plazmi.
Adverse reactions from post-marketing surveillance has been gathered covering an estimated period > 10 years. 
Nuspojave nakon stavljanja lijeka u promet prikupljene su u razdoblju procijenjenom na >10 godina.
Doses of 200 mg did not result in increased efficacy but the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, altered vision) was increased. 
Doze od 200 mg nisu rezultirale povećanom djelotvornošću, već je porasla incidencija nuspojava (glavobolja, naleti crvenila, omaglica, dispepsija, nazalna kongestija, promjenjen vid).
Sildenafil is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4). 
Sildenafil je kontraindiciran u bolesnika koji su izgubili vid na jednom oku zbog nearteritične anteriorne ishemijske optičke neuropatije (NAION), bez obzira je li ta epizoda bila u vezi ili ne s prethodnom izloženošću PDE5 inhibitoru (vidjeti dio 4.4).
- Serious skin reactions - this occurs rarely. 
Ozbiljne kožne reakcije - javljaju se rijetko.
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. 
Riociguat: Pretklinička ispitivanja pokazala su aditivan učinak na snižavanje krvnog tlaka kada su se inhibitori PDE5 primjenjivali u kombinaciji sa riociguatom.
Do NOT take Sildenafil ratiopharm: - if you are allergic to sildenafil or any of the other ingredients of this medicine (listed in section 
NEMOJTE uzimati Sildenafil ratiopharm - ako ste alergični na sildenafil ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
How to store Sildenafil ratiopharm Contents of the pack and other information 
Kako čuvati Sildenafil ratiopharm Sadržaj pakiranja i druge informacije
The following patient groups were represented: elderly (19.9%), patients with hypertension (30.9%), diabetes mellitus (20.3%), ischaemic heart disease (5.8%), hyperlipidaemia (19.8%), spinal cord injury (0.6%), depression (5.2%), transurethral resection of the prostate (3.7%), radical prostatectomy (3.3%). 
Zastupljene su sljedeće skupine bolesnika: stariji (19,9%), bolesnici s hipertenzijom (30,9%), dijabetes melitusom (20,3%), ishemijskom bolesti srca (5,8%), hiperlipidemijom (19,8%), ozljedom leđne moždine (0,6%), depresijom (5,2%), transuretralnom resekcijom prostate (3,7%), radikalnom prostatektomijom (3,3%).
ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Germany 
ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Njemačka
Due to age-differences in plasma protein binding, the corresponding increase in free sildenafil plasma concentration was approximately 
Zbog dobnih razlika u vezanju na proteine plazme, odgovarajući porast koncentracija slobodnog sildenafila u plazmi iznosio je približno 40%.
Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP. 
Sildenafil je jak i selektivan inhibitor cGMP specifične fosfodiesteraze tipa 5 (PDE5) u korpus kavernozumu, gdje je PDE5 odgovorna za razgradnju cGMP.
In fixed dose studies, the proportions of patients reporting that treatment improved their erections were 62% (25 mg), 74% (50 mg) and 82% (100 mg) compared to 25% on placebo. 
U ispitivanjima s fiksnom dozom, udjeli bolesnika koji su prijavili da im je liječenje poboljšalo erekciju iznosili su 62% (25 mg), 74% (50 mg) i 82% (100 mg) u usporedbi s 25% kod placeba.
In a medical emergency, you must tell anyone treating you that you have taken Sildenafil ratiopharm. 
U hitnim slučajevima, liječniku morate reći da ste uzeli Sildenafil ratiopharm.
Sudden cardiac death*, Myocardial infarction, Ventricular arrhythmia*, Atrial fibrillation, Unstable angina 
Iznenadna srčana smrt,* infarkt miokarda, ventrikularna aritmija,* fibrilacija atrija, nestabilna angina
Based on these pharmacokinetic results co-administration of sildenafil with ritonavir is not advised (see section 4.4) and in any event the maximum dose of sildenafil should under no circumstances exceed 25 mg within 48 hours. 
S obzirom na te farmakokinetičke rezultate, istodobna primjena sildenafila s ritonavirom se ne preporučuje (vidjeti dio 4.4) te ni u kom slučaju maksimalna doza sildenafila ne smije premašiti 25 mg unutar 48 sati.
Somnolence, Hypoaesthesia 
Somnolencija, hipoestezija
The dosing recommendations described in ‘Use in adults' apply to patients with mild to moderate renal impairment (creatinine clearance = 30-80 mL/min). 
Preporuke za doziranje opisane pod „Primjena u odraslih osoba“ odnose se na bolesnike s blagim do umjerenim oštećenjem funkcije bubrega (klirens kreatinina = 30-80 ml/min).
When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP. 
Kada je NO/cGMP put aktiviran, što se događa uz seksualnu stimulaciju, inhibicija PDE5 sildenafilom rezultira povećanim vrijednostima cGMP u korpus kavernozumu.
Prior to prescribing sildenafil, physicians should carefully consider whether their patients with certain underlying conditions could be adversely affected by such vasodilatory effects, especially in combination with sexual activity. 
Prije propisivanja sildenafila, liječnici moraju brižljivo razmotriti mogu li takvi vazodilatatorni učinci štetno utjecati na njihove bolesnike s određenim primarnim bolestima, osobito u kombinaciji sa spolnom aktivnošću.
Agents for the treatment of erectile dysfunction, including sildenafil, should not be used in men for whom sexual activity is inadvisable (e.g. patients with severe cardiovascular disorders such as unstable angina or severe cardiac failure). 
Sredstva za liječenje erektilne disfunkcije, uključujući sildenafil, ne smiju koristiti muškarci kojima se spolna aktivnost ne preporučuje (npr. bolesnici s teškim kardiovaskularnim poremećajima kao što su nestabilna angina ili teško zatajenje srca).
Sildenafil ratiopharm contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. 
Sildenafil ratiopharm sadrži djelatnu tvar sildenafil koja pripada skupini lijekova pod nazivom inhibitori fosfodiesteraze tipa 5 (PDE5).
PDE5 inhibitors, such as sildenafil, have been shown to increase the hypotensive effects of this medicine. 
Inhibitori PDE5, kao što je sildenafil, pokazali su da povećavaju hipotenzivne učinke ovog lijeka.
Studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside in vitro. 
Ispitivanja s ljudskim trombocitima pokazuju da sildenafil pojačava antiagregacijski učinak natrijevog nitroprusida in vitro.